Psychedelic and ketamine research trials in Germany
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
10 registered studies are counted in Germany. By compound: 3 psilocybin, 1 5-MeO-DMT and 6 ketamine. By registry status: 3 recruiting, 5 completed, 1 terminated and 1 status not reported. By phase: 2 phase 1, 4 phase 2, 1 phase 4 and 3 not applicable. Reported start years run from 2010 (earliest) to 2024 (latest). Studies are linked to 10 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
3 of the 10 counted studies are listed in the registry as recruiting (3) or not yet recruiting (0), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| At-Home tDCS as Maintenance Therapy | NCT07269964 | Recruiting | Not applicable | 2024-10-01 | Technical University of Munich, München |
| Pharmacologic Treatment Augmentation in Chronic Depression | NCT06410599 | Recruiting | Phase 2 | 2024-04-29 | University Hospital Tuebingen, Tübingen |
| The Neurobiological Effect of 5-HT2AR Modulation | NCT03289949 | Recruiting | Phase 1 | 2017-03-03 | Rigshospitalet, Denmark, Copenhagen |
At a glance
- 10 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 3 |
| 5-MeO-DMT | 1 |
| Ketamine | 6 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 3 | 30% |
| Completed | 5 | 50% |
| Terminated | 1 | 10% |
| Status not reported | 1 | 10% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 2 | 20% |
| Phase 2 | 4 | 40% |
| Phase 4 | 1 | 10% |
| Not applicable | 3 | 30% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 2 |
| 2020 to 2023 | 4 |
| 2015 to 2019 | 2 |
| 2010 to 2014 | 2 |
All counted studies
All 10 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| At-Home tDCS as Maintenance Therapy | NCT07269964 | Recruiting | Not applicable | 2024-10-01 | Technical University of Munich, München |
| Pharmacologic Treatment Augmentation in Chronic Depression | NCT06410599 | Recruiting | Phase 2 | 2024-04-29 | University Hospital Tuebingen, Tübingen |
| Phase 2 Clinical Trial of GH001 in Bipolar II Disorder | NCT05839509 | Terminated | Phase 2 | 2023-04-06 | GH Research Ireland Limited, Dresden |
| Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study | NCT04718792 | Status not reported | Phase 2 | 2023-02-09 | Psychiatric Centre Rigshospitalet, Copenhagen |
| Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression | NCT04670081 | Completed | Phase 2 | 2021-06-10 | Central Institute of Mental Health, Mannheim, Berlin |
| Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine | NCT04156035 | Completed | Not applicable | 2020-03-10 | Charite University, Berlin, Germany, Berlin |
| Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers | NCT05320991 | Completed | Phase 4 | 2019-06-15 | University Hospital, Bonn, Bonn |
| The Neurobiological Effect of 5-HT2AR Modulation | NCT03289949 | Recruiting | Phase 1 | 2017-03-03 | Rigshospitalet, Denmark, Copenhagen |
| Effects of Ketamine on Eye Movements, Perception and Brain Function | NCT02701933 | Completed | Not applicable | 2014-04-01 | University of Bonn, Bonn |
| Ketamine Challenge Study With JNJ-40411813 | NCT01101659 | Completed | Phase 1 | 2010-02-01 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Neuss |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | 5-MeO-DMT | Ketamine
Institution hubs in this country
Institutions in this country with at least 3 counted studies. The number is that institution's own count of studies, which can include studies not shown above if the registry lists them under another country.
- Rigshospitalet, Denmark: 3 studies
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 3 |
| Alcohol use disorder | 1 |
| Bipolar disorder | 1 |
| Treatment-resistant depression | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | France | Israel | Brazil | China | Netherlands | Australia | Austria | Spain | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark | Finland